INCB024360

Min.Order / FOB Price:Get Latest Price

100 Gram	FOB Price: USD 1.0000

100 Gram

FOB Price: USD 1.0000

Min.Order :100 Gram
Purity: 98%
Payment Terms : L/C

Keywords

INCB024360 INCB 024360;INCB024360;INCB-024360;INCB-24360;indoleaMine-2,3-dioxygenase inhibitor INCB024360;INCB024360/INCB-024360;4-Amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide; 914471-09-3

Quick Details

Appearance:white crystalline solid
Application:CAS：914471-09-3； INCB 024360;INCB024360;INCB-024360;INCB-24360;indoleaMine-2,3-dioxygenase inhibitor INCB024360;INCB024360/INCB-024360;4-Amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazol
PackAge:100g,500,1kg.....
ProductionCapacity:100|Gram|Month
Storage:Dry seal
Transportation:shipping

Superiority:

We are specialized in custom synthesis, chemical/pharmaceutical/ pesticides outsourcing and contract research.

We are committed to provide excellence in researching, manufacturing and drug discovery process.

Our research team of scientists consists of western-trained Ph.D.s with experience and capabilities in drug R&D methodologies and medicinal chemistry.

Details:

IDO-IN-2 is a potent IDO1 inhibitor(IC50=10 nM) with desirable pharmaceutical properties, which is poised to start clinical trials in cancer patients.
IC50 Value: 10 nM [1]
Target: IDO1
in vitro: In cellular assays,IDO-IN-2 selectively inhibits human IDO1 with IC(50) values of approximately 10nM, demonstrating little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO) [1]. In coculture systems of human allogeneic lymphocytes with dendritic cells (DCs) or tumor cells,IDO-IN-2 inhibition of IDO1 promotes T and natural killer (NK)-cell growth, increases IFN-gamma production, and reduces conversion to regulatory T (T(reg))-like cells. IDO1 induction triggers DC apoptosis, whereas IDO-IN-2 reverses this and increases the number of CD86 (high) DCs, potentially representing a novel mechanism by which IDO1 inhibition activates T cells [1].
in vivo: Consistent with its effects in vitro, administration of IDO-IN-2 to tumor-bearing mice significantly inhibits tumor growth in a lymphocyte-dependent manner [1]. A single dose of IDO-IN-2 or IDO-IN-2 results in efficient and durable suppression of Ido1 activity in the plasma of treated mice and dogs, the former to levels seen in Ido1-deficient mice [2].
Clinical trial: A Phase 2 Study of the IDO Inhibitor IDO-IN-2 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy.

View All